The FDA has upped its drug safety game since the last edition of Guide to FDA Drug Safety Regulation, adding more than 30 new, revised and finalized pharmacovigilance guidances, 12 of them in 2015-2017 alone. The new guide has them all:
Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data (2013)
Form and Content of a REMS Document (2017)
Nonclinical Safety Evaluation of Reformulated Drug Products (2016)
Providing Postmarketing Periodic Safety Reports in the ICH E2C (R2) Format (2016)
Safety Considerations for Product Design to Minimize Medication Errors (2016)
Postmarket Submission of Individual Case Safety Reports for Drugs and Biologics (2016)
Photosafety Evaluation of Pharmaceuticals (2015)
You’ll also find the long-standing documents on which you’ve built your postmarket surveillance program, including:
Development and Use of Risk Minimization Action Plans
Good Pharmacovigilance Practices
Nonclinical Safety Evaluation of Drug or Biologic Combinations
Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients
Premarketing Risk Assessment
Guide to FDA Drug Safety Regulation will help you keep up with the FDA’s evolving drug safety requirements as the agency tries to speed drug development and lower prices.
Order Your Copy Today
PDF Edition — $397
Who Will Benefit
Compliance and regulatory affairs
Postmarket surveillance staff
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.